Clinical trials: MALT Lymphoma, open to volunteers
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia (HCL)
- Trial name
- IMPACT (NCT07759661)
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS San Raffaele
MALT Lymphoma of Stomach
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
We hypothesized that a proportion of patients with localized Helicobacter pylori-negative gastric MALT lymphoma may well respond to frontline Helicobacter pylori eradication therapy (HPE) and remain lymphoma-free for the long…
- Trial name
- GastricMALToma (NCT07144657)
- Testing
- Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
- Conditions
- B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma
- Trial name
- NCT07168486
- Testing
- CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Marginal Zone Lymphoma
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma
- Trial name
- NCT06478472
- Testing
- Orelabrutinib in combination with rituximab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Marginal Zone Lymphoma
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma.
- Trial name
- NCT06454968
- Testing
- Orelabrutinib, obinutuzumab, lenalidomide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
Marginal Zone Lymphoma(MZL)
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.
- Trial name
- ZanOs (NCT06823960)
- Where
- 15 sites in Italy
- Volunteers
- 59 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL)
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL), Waldenstrom Macroglobulinaemia, Lymphoplasmacytic Lymphoma
- Trial name
- HEMO-CONNECT (NCT07592481)
- Testing
- Connected home blood pressure monitoring with daily IPA supervision.
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier de la côte Basque
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Marginal Zone Lymphoma(MZL)
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
This study focuses on treatment-naïve marginal zone lymphoma (MZL) patients and aims to investigate the efficacy and safety of orelabrutinib combined with or without CD20 monoclonal antibody.
- Trial name
- NCT07355699
- Testing
- Orelabrutinib
- Where
- 3 sites in China
- Volunteers
- 88 people
- Sponsor
- Beijing Tongren Hospital
Marginal Zone Lymphoma
A Cohort Study in Newly Diagnosed MZL
Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment…
- Trial name
- NCT06449885
- Testing
- patients receive optimal treatment or follow-up according to the characteristics of the disease
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- Fudan University
Mantle Cell Lymphoma, Follicular Lymphoma
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells…
- Conditions
- Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT04223765
- Testing
- CAR.k.28, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
B-cell Malignancy, Chronic Lymphocytic Leukemia
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
- Conditions
- B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT05602363
- Testing
- Docirbrutinib
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Carna Biosciences, Inc.
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to…
- Conditions
- Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT07713459
- Testing
- CART Infusion
- Volunteers
- 105 people
- Sponsor
- Kure Cells, INC
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Marginal Zone Lymphoma(MZL)
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL
- Trial name
- NCT06700798
- Testing
- Orelabrutinib, rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fei Li
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell…
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT05990465
- Testing
- Pirtobrutinib, LV20.19 CAR T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Marginal Zone Lymphoma(MZL)
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
This is a multicenter, phase 2, randomized trial to compare rituximab maintenance with observation after rituximab and lenalidomide (R2) induction therapy in patients with previously untreated marginal zone lymphoma.
- Trial name
- ROMA (NCT07654465)
- Testing
- Rituximab, Observation
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Marginal Zone Lymphoma
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL).
- Conditions
- Lymphoma, Marginal Zone Lymphoma, MZL
- Trial name
- NCT06510309
- Testing
- Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Gottfried von Keudell, MD PhD
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center